SNX29: A Potential Drug Target Or Biomarker for Neurodegenerative and Cancer-Related Diseases
SNX29: A Potential Drug Target Or Biomarker for Neurodegenerative and Cancer-Related Diseases
SNX29, also known as RUN domain containing 2A (RUN-GTPase-activating protein 2A), is a protein that is expressed in various tissues and cells of the human body. It plays a crucial role in the regulation of cell signaling pathways, including the Run/GTP signaling pathway. This pathway is involved in many cellular processes, including cell growth, differentiation, and survival. Therefore, SNX29 has been identified as a potential drug target or biomarker for various diseases.
The Run/GTP signaling pathway is a complex regulatory system that involves the interaction between the protein GTPase and the protein GDP. The GTPase activity of the protein is regulated by the interaction with GDP, which is a protein that binds to a specific GTP binding site on the protein. The RUN domain is a part of the protein that contains the GTPase active site, where the GDP binds to the protein. The activity of the RUN domain is regulated by various factors, including the concentration of GDP, the activity of other proteins that interact with the RUN domain, and the presence of bound GDP.
SNX29 is a 21-kDa protein that is expressed in various tissues and cells of the human body. It is highly conserved and has a similar structure to other RUN domain-containing proteins. The protein has a molecular weight of 43.9 kDa and a pre-steady state nitrogen equivalent (N) value of 19.9 kDa. SNX29 is expressed in the brain, heart, skeletal muscles, and other tissues of the human body. It is highly expressed in the brain, with a ratio of 11.1 to 106 copies per million cell.
SNX29 is involved in the regulation of many cellular processes, including cell signaling pathways, including the Run/GTP signaling pathway. This pathway is involved in many cellular processes, including cell growth, differentiation, and survival. Therefore, SNX29 has been identified as a potential drug target or biomarker for various diseases.
One of the potential benefits of targeting SNX29 is its potential role in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neurodegeneration. SNX29 has been shown to be involved in the regulation of neurotransmitter release from neurons, which is critical for the function of these diseases.
Another potential benefit of targeting SNX29 is its potential role in the treatment of cancer. Cancer is a leading cause of death in the world, and its development and progression are influenced by many factors, including the regulation of cell signaling pathways. SNX29 has been shown to be involved in the regulation of cell signaling pathways, including the Run/GTP signaling pathway. Therefore, targeting SNX29 may be a promising approach to the treatment of cancer.
In addition to its potential therapeutic applications, SNX29 also has potential as a biomarker for various diseases. The regulation of cell signaling pathways, including the Run/GTP signaling pathway, is a critical factor in the development and progression of many diseases. Therefore, the activity of SNX29 may be a useful biomarker for the diagnosis and prognosis of these diseases.
In conclusion, SNX29 is a protein that is expressed in various tissues and cells of the human body. It plays a crucial role in the regulation of cell signaling pathways, including the Run/GTP signaling pathway. The protein has been identified as a potential drug target or biomarker for various diseases, including neurodegenerative diseases and cancer. Further research is needed to fully understand the role of SNX29 in these diseases and to develop effective treatments.
Protein Name: Sorting Nexin 29
The "SNX29 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNX29 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
SNX29P1 | SNX29P2 | SNX3 | SNX30 | SNX31 | SNX32 | SNX33 | SNX4 | SNX5 | SNX6 | SNX7 | SNX8 | SNX9 | SOAT1 | SOAT2 | SOBP | SOCAR | SOCS1 | SOCS2 | SOCS2-AS1 | SOCS3 | SOCS3-DT | SOCS4 | SOCS5 | SOCS5P5 | SOCS6 | SOCS7 | SOD1 | SOD2 | SOD2-OT1 | SOD3 | Sodium channel | Sodium-Glucose Cotransporter (SGLT) | Sodium-potassium-calcium exchanger | SOGA1 | SOGA3 | SOHLH1 | SOHLH2 | Soluble (cytosolic) protein tyrosine phosphatases | Soluble guanylyl cyclase | Solute Carrier Family 12 | Solute carrier family 29 member | Somatostatin receptor | SON | SORBS1 | SORBS2 | SORBS3 | SORCS1 | SORCS2 | SORCS3 | SORCS3-AS1 | SORD | SORD2P | SORL1 | SORT1 | Sorting and assembly machinery complex | Sorting nexin | SOS1 | SOS2 | SOSS complex | SOST | SOSTDC1 | SOWAHA | SOWAHB | SOWAHC | SOWAHD | SOX1 | SOX1-OT | SOX10 | SOX11 | SOX12 | SOX13 | SOX14 | SOX15 | SOX17 | SOX18 | SOX2 | SOX2-OT | SOX21 | SOX21-AS1 | SOX3 | SOX30 | SOX30P1 | SOX4 | SOX5 | SOX5-AS1 | SOX6 | SOX7 | SOX8 | SOX9 | SOX9-AS1 | SP1 | SP100 | SP110 | SP140 | SP140L | SP2 | SP2-AS1 | SP3 | SP3P
